SKB264

SKB264 (sacituzumab tirumotecan, also MK-2870) is a TROP2-targeted antibody-drug conjugate developed by Sichuan Kelun-Biotech, which Merck licensed for ex-China rights in May 2022 for $47M upfront plus up to ~$1.36B in milestones, with tiered royalties on net sales - Kelun retains Greater China rights and an undisclosed royalty stream on Merck's ex-China sales [1]. Merck is running at least six Phase 3 trials across breast (TNBC and HR+/HER2-), lung, ovarian, cervical, and urothelial cancers - a sprawling development program that reads like Merck trying to install a TROP2 ADC as the next backbone of oncology after Keytruda (pembrolizumab) loses US exclusivity in 2028. The drug is already approved in China (November 2024) for third-line triple-negative breast cancer [2]; the question now is whether it can take share from Gilead's Trodelvy (sacituzumab govitecan) and AstraZeneca/Daiichi's newly-approved Datroway (datopotamab deruxtecan) in Western markets.

Globally a Phase 3 investigational asset; in China, an approved drug. Sac-TMT received its first NMPA (China's National Medical Products Administration) approval in November 2024 for pretreated locally advanced or metastatic TNBC (triple-negative breast cancer) based on OptiTROP-Breast01 [2], and a second NMPA approval in August 2025 for EGFR-mutant NSCLC (non-small cell lung cancer) post-TKI (tyrosine kinase inhibitor). In the US and EU, no approvals yet. Merck has not publicly disclosed FDA Breakthrough Therapy Designation, Fast Track, or Orphan Drug Designation for any sac-TMT indication, though the company has signaled the EGFR-mutant NSCLC readout (MK-2870-009) and the HR+/HER2- breast cancer program are priority filings. The active Phase 3 slate covers: (1) EGFR-mutant NSCLC post-TKI (NCT06305754, n=520, active not recruiting - readout expected 2026) [3]; (2) first-line PD-L1-high NSCLC in combination with pembrolizumab vs pembrolizumab alone (NCT06170788, n=614) [4]; (3) HR+/HER2- breast cancer post-endocrine/CDK4/6 - TroFuse-010 (NCT06312176), sac-TMT monotherapy or sac-TMT + pembrolizumab vs treatment of physician's choice chemotherapy [12]; (4) platinum-sensitive ovarian maintenance (NCT06824467, n=770) [5]; (5) urothelial cancer (NCT07419295, n=590) [6]; and (6) first-line cervical maintenance with pembrolizumab ± bevacizumab (NCT07216703, n=1023) [7]. EGFR-mutant NSCLC is the nearest catalyst.

TROP2 (gene name TACSTD2) is a protein that sits on the surface of many epithelial cancer cells - breast, lung, bladder, cervix, ovary - and turns up cell growth signaling. Healthy tissues express it at lower levels, which is what makes it a half-decent address label for an ADC: high enough on tumors to deliver a payload, low enough on normal cells to avoid catastrophic off-target damage. The drug is a humanized anti-TROP2 antibody tethered to a topoisomerase I inhibitor payload called KL610023 (a belotecan derivative) via a hydrolyzable sulfonyl linker, with a drug-to-antibody ratio of roughly 7.4 - meaning each antibody drags about seven payload molecules into the cell. Once the ADC binds TROP2 and gets internalized, the linker releases the payload, which jams topoisomerase I and triggers DNA damage that kills dividing cells. The payload is also designed to leak into neighboring tumor cells (the bystander effect), which matters because TROP2 expression is heterogeneous. Target validation is real: sacituzumab govitecan (Trodelvy) is already approved against TROP2 in TNBC and HR+/HER2- breast cancer, and datopotamab deruxtecan (Datroway) is approved in HR+/HER2- breast cancer. SKB264 is differentiated by linker chemistry and DAR, not by hitting a novel target.

The most consequential near-term readout is MK-2870-009 (NCT06305754): a Phase 3 head-to-head of sac-TMT monotherapy vs pemetrexed-carboplatin in EGFR-mutant nonsquamous NSCLC that has progressed on prior EGFR TKIs (read: post-osimertinib) [3]. N=520, OS (overall survival) primary endpoint, status: active not recruiting. This is a clean unmet need - post-TKI patients have no good chemo option (~20,000-25,000 US patients progress past osimertinib annually, with median post-progression survival under 18 months) - and the comparator is realistic. Phase 2 data published in Nat Med (2025) showed confirmed ORR of 34% and median PFS (progression-free survival) of 9.3 months in 64 EGFR-mutant patients [8]. MK-2870-007 (NCT06170788) is the more ambitious bet: sac-TMT + pembrolizumab vs pembrolizumab monotherapy in first-line PD-L1-high (TPS ≥50% - Tumor Proportion Score, the percentage of tumor cells staining positive for PD-L1) NSCLC, n=614, OS primary [4]. Beating Keytruda monotherapy in PD-L1-high is hard - that's been the graveyard for multiple combinations - but Merck has supporting Phase 2 combo data with tagitanlimab [9]. TroFuse-010 (NCT06312176) addresses HR+/HER2- breast cancer post-CDK4/6 inhibitor failure - a ~40,000-patient/year US market that is the largest single commercial prize in the program and the indication where Datroway already has a US approval; Phase 1/2 sac-TMT monotherapy ORR was 36.8% in this population [12]. The ovarian maintenance trial (NCT06824467) and cervical 1L maintenance trial (NCT07216703) are large (770 and 1023 patients) and use standard-of-care comparators. Designs are conventional; the risk is in the biology, not the protocols.

Our model gives this drug a 22% chance of eventually being approved. That number starts from the historical approval rate of about 48% for Phase 3 drugs in this area, then adjusts based on ten facts about the trial and its sponsor. The estimate is pushed up by an above-average number of secondary endpoints and light or open-label blinding, but pulled down by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The remaining factors were close to average, so they left the estimate roughly where it started.

Efficacy risk: the 1L PD-L1-high NSCLC trial (MK-2870-007) is the program's biggest swing - combinations have historically struggled to add OS benefit on top of pembrolizumab monotherapy in this exact population. If it fails, it's not a death blow to the asset, but it removes the most lucrative indication. Safety risk: topoisomerase I payload ADCs carry mechanism-based ILD (interstitial lung disease - scarring/inflammation of lung tissue) and pneumonitis risk; Enhertu's label carries a black-boxed ILD warning, and Trodelvy has seen severe neutropenia and diarrhea. Sac-TMT's pooled Phase 2 NSCLC data showed ILD/pneumonitis at 2.2% across treatment arms - favorable versus Enhertu's 10-15% real-world rate but the number to watch in Phase 3 [8]. Other Phase 2 toxicities included stomatitis (mouth sores) and cytopenias (low blood cell counts), manageable but real [8]. ILD signal will be the FDA's first question on any submission. Competitive risk is the most underrated: AstraZeneca/Daiichi got Datroway approved in HR+/HER2- breast cancer in January 2025, and Gilead's Trodelvy is entrenched in TNBC. Sac-TMT enters Western markets as a third TROP2 ADC, not first or second. Payers will demand head-to-head superiority or a meaningful price discount. Execution risk is low - this is Merck - but the China-developed asset means CMC (Chemistry, Manufacturing, and Controls - the quality systems and process documentation FDA reviews) will get extra FDA scrutiny relative to a fully-Merck molecule.

Worth watching. This is a real asset with real Phase 2 data and a $1.4B+ commitment from Merck - not vapor. The signal to watch: MK-2870-009 OS readout in EGFR-mutant NSCLC post-TKI, expected in 2026. If sac-TMT shows a clean OS benefit over chemo in this population, Merck has a fast-track filing and a differentiated entry into a desperate market (US post-TKI EGFR-mutant NSCLC ≈ 20-25K patients/year, $2-3B addressable). If it shows only PFS benefit with no OS separation, it's a tougher commercial story given Datroway and Trodelvy already exist. The second signal: any ILD rate disclosed in the Phase 3 readouts above 8-10% would compress the commercial opportunity meaningfully - the 2.2% Phase 2 baseline is the number to anchor on. Connect to the money: Merck's Keytruda is ~$30B/year and loses US exclusivity in 2028. Sac-TMT is one of three or four assets internally tagged as 'must-work' to bridge the Keytruda cliff (alongside MK-1084 and the Daiichi-licensed I-DXd). The HR+/HER2- breast cancer indication (TroFuse-010) is the single largest commercial prize in the program - a ~$8-12B addressable market - but also the most contested, with Datroway already on label. For Sichuan Kelun-Biotech (HKEX:6990), sac-TMT royalties on Merck's ex-China sales are already material to the equity story; the exact royalty tier structure is undisclosed but estimated by analysts at low double digits. Check back after the 2026 ASCO and ESMO cycles.